Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Updates on the Genetics of Myeloid Malignancies
share announcement

Updates on the Genetics of Myeloid Malignancies

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".

Deadline for manuscript submissions: closed (25 November 2024) | Viewed by 5933

Special Issue Editor

Dr. Valeria Visconte

E-Mail Website
Guest Editor
Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA
Interests: myeloid malignancies; bone marrow failure syndromes; RNA splicing
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues, 

Myeloid malignancies are clonal hematopoietic disorders characterized by the presence of mutations in hematopoietic progenitors. The application of modern genome sequencing has provided clues to identify novel mutated gene pathways and their roles in disease pathogenesis. Computer science has created the possibility to build algorithms and bioinformatics tools to incorporate a variety of genomic information possibly leading to improvement in the selection of therapeutics in the near future.

This special issue is open to original research articles and reviews on the scope of genetics and genomics of myeloid malignancies. Submissions on artificial intelligence and novel computational methods on genetics features of myeloid malignancies is highly encouraged.

Dr. Valeria Visconte
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • myeloid malignancies
  • genetics
  • genomics
  • artificial intelligence
  • novel computational methods

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Editorial

Jump to: Review

5 pages, 596 KiB  
Editorial
The Heterogeneous Complexity of Myeloid Neoplasm: Multi-Level Approaches to Study the Disease
by Hussein Awada and Valeria Visconte
Cancers 2023, 15(5), 1449; https://doi.org/10.3390/cancers15051449 - 24 Feb 2023
Viewed by 1422
Abstract
Myeloid neoplasms (MNs) include a spectrum of bone marrow malignancies that result from the clonal expansion and arrest of differentiation of myeloid progenitor cells [...] Full article
(This article belongs to the Special Issue Updates on the Genetics of Myeloid Malignancies)
►▼ Show Figures

Figure 1

Review

Jump to: Editorial

15 pages, 680 KiB  
Review
Fusion Genes in Myeloid Malignancies
by Chieh Hwee Ang, Hein Than, Tertius T. Tuy and Yeow Tee Goh
Cancers 2024, 16(23), 4055; https://doi.org/10.3390/cancers16234055 - 3 Dec 2024
Viewed by 729
Abstract
Fusion genes arise from gross chromosomal rearrangements and have been closely linked to oncogenesis. In myeloid malignancies, fusion genes play an integral role in the establishment of diagnosis and prognostication. In the clinical management of patients with acute myeloid leukemia, fusion genes are [...] Read more.
Fusion genes arise from gross chromosomal rearrangements and have been closely linked to oncogenesis. In myeloid malignancies, fusion genes play an integral role in the establishment of diagnosis and prognostication. In the clinical management of patients with acute myeloid leukemia, fusion genes are deeply incorporated in risk stratification criteria to guide the choice of therapy. As a result of their intrinsic ability to define specific disease entities, oncogenic fusion genes also have immense potential to be developed as therapeutic targets and disease biomarkers. In the current era of genomic medicine, breakthroughs in innovation of sequencing techniques have led to a rise in the detection of novel fusion genes, and the concept of standard-of-care diagnostics continues to evolve in this field. In this review, we outline the molecular basis, mechanisms of action and clinical impact of fusion genes. We also discuss the pros and cons of available methodologies that can be used to detect fusion genes. To contextualize the challenges encountered in clinical practice pertaining to the diagnostic workup and management of myeloid malignancies with fusion genes, we share our experience and insights in the form of three clinical case studies. Full article
(This article belongs to the Special Issue Updates on the Genetics of Myeloid Malignancies)
►▼ Show Figures

Figure 1

18 pages, 1866 KiB  
Review
Single-Cell Next-Generation Sequencing to Monitor Hematopoietic Stem-Cell Transplantation: Current Applications and Future Perspectives
by Olisaemeka Ogbue, Serhan Unlu, Gogo-Ogute Ibodeng, Abhay Singh, Arda Durmaz, Valeria Visconte and John C. Molina
Cancers 2023, 15(9), 2477; https://doi.org/10.3390/cancers15092477 - 26 Apr 2023
Cited by 2 | Viewed by 3058
Abstract
Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are genetically complex and diverse diseases. Such complexity makes challenging the monitoring of response to treatment. Measurable residual disease (MRD) assessment is a powerful tool for monitoring response and guiding therapeutic interventions. This is accomplished [...] Read more.
Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are genetically complex and diverse diseases. Such complexity makes challenging the monitoring of response to treatment. Measurable residual disease (MRD) assessment is a powerful tool for monitoring response and guiding therapeutic interventions. This is accomplished through targeted next-generation sequencing (NGS), as well as polymerase chain reaction and multiparameter flow cytometry, to detect genomic aberrations at a previously challenging leukemic cell concentration. A major shortcoming of NGS techniques is the inability to discriminate nonleukemic clonal hematopoiesis. In addition, risk assessment and prognostication become more complicated after hematopoietic stem-cell transplantation (HSCT) due to genotypic drift. To address this, newer sequencing techniques have been developed, leading to more prospective and randomized clinical trials aiming to demonstrate the prognostic utility of single-cell next-generation sequencing in predicting patient outcomes following HSCT. This review discusses the use of single-cell DNA genomics in MRD assessment for AML/MDS, with an emphasis on the HSCT time period, including the challenges with current technologies. We also touch on the potential benefits of single-cell RNA sequencing and analysis of accessible chromatin, which generate high-dimensional data at the cellular resolution for investigational purposes, but not currently used in the clinical setting. Full article
(This article belongs to the Special Issue Updates on the Genetics of Myeloid Malignancies)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop